Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides ...
Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets; Initial multi-target sublicense deal executed with stealth ADC company
By Pyxis Oncology
Published - Nov 01, 2022, 06:32 AM ET
Last Updated - Apr 18, 2024, 06:26 AM EDT
Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components
Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets; Initial multi-target sublicense deal executed with stealth ADC company
Remains on track with IND plans for PYX-106 and PYX-201 by the end of this year
Strong balance sheet with $200 million in cash (including restricted cash) as of September 30, 2022 maintainsflexibility to pursue business development opportunities
